Persistent Depressive DisorderPePsyNCT03616665
Feasibility and Effectiveness of a Personalized Inpatient Program for Persistent Depressive Disorder
A study testing CBASPersonalized in people with Persistent Depressive Disorder, run by Philipps University Marburg at 2 sites in Germany.
Trial summary
The major objective of this study is to evaluate a new conceptualized personalized concept of Cognitive Behavioral Analysis System of Psychotherapy (CBASPersonalized) in the treatment of patients with persistent depressive disorder (PDD), childhood maltreatment and a high rate of comorbidity. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Persistent Depressive Disorder
- What is being tested?
- CBASPersonalized
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 2 sitesGermany
- Study dates
- 1 Apr 2019to 30 Sep 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Primary diagnosis of persistent depressive disorder (PDD) according to DSM-5
- Experiences of childhood maltreatment (>Cut-off criteria in one of 5 scales of the Childhood Trauma Screener (CTS))
- Sufficient German language skills
- Have read and signed an informed consent form
Who cannot join
- Life-time diagnosis of an schizophrenia or schizophrenic spectrum disorder according to DSM-5
- Life-time diagnosis of a schizoid, schizotypal or antisocial personality disorder according to DSM-5
- Consumption of legal (e.g. alcohol) or illegal substances during the inpatient stay
Trial locations and contacts
2 sites in 1 country.
Germany2 sites, 2 recruiting
- Recruiting
Schoen Klinik Bad Arolsen
Bad Arolsen, Hesse, 34454
Thomas Gaertner, Dr. med., +49 5691 6238-3099, tgaertner@schoen-kliniken.de
- Recruiting
Philipps University Marburg, Faculty psychology, department clinical psychology
Marburg, Hesse, 35032
Winfried Rief, Prof. Dr., +49 6421 28-23657, rief@staff.Uni-Marburg.DE
About this study
Official title: Feasibility and Effectiveness of a Personalized Inpatient Program Tailored for Persistent Depressive Disorder With Childhood Maltreatment and Comorbidity: Personalized Cognitive Behavioral Analysis System of Psychotherapy
The major objective of this study is to evaluate a new conceptualized personalized concept of Cognitive Behavioral Analysis System of Psychotherapy (CBASPersonalized) in the treatment of patients with persistent depressive disorder (PDD), childhood maltreatment and a high rate of comorbidity. Patients receive a two-phase-treatment-program (six-weeks inpatient-treatment and six-to-twelve-weeks blended-online-aftercare) in combination with standardized pharmacotherapy in a routine clinical inpatient setting. This study addresses the primary research question: Is an intensive six-week inpatient CBASPersonalized treatment feasible and effective in a clinical sample of PDD patients? In addition, moderator, process and long-term analyses will be conducted for differential insights.
Read the detailed description
Background: Persistent depressive disorder (PDD) is a prevalent disabling disorder. Given its high degree of treatment-resistance (TR), comorbidity, and suicidality, this patient group constitutes a massive health problem. The Cognitive Behavioral Analysis System of Psychotherapy (CBASP) was specifically developed for the outpatient treatment of PDD showing superiority to active control groups in some studies. However, non-remission and relapse rates of CBASP are relatively high, which might be caused by the fact that within the original CBASP-concept the frequent comorbid disorders are not sufficiently addressed. Thus, an optimized personalized short and intensive CBASP-concept (CBASPersonalized) was established including the interpersonal CBASP-strategies while adding evidence-based intrapersonal strategies being tailored to the specific comorbid problems. In this study, the investigators will evaluate the feasibility and effectiveness of CBASPersonalized. Patients will receive a six-week inpatient treatment followed by a six-to-twelve-week blended-online-aftercare (CBASPersonalized@home) in combination with standardized pharmacotherapy in a routine clinical inpatient setting.
Methods: In the proposed prospective, mono-site study, 100 PDD patients with childhood maltreatment will be included. The study addresses the primary research question: Is an intensive six-week inpatient CBASPersonalized treatment feasible and effective in a clinical sample of PDD patients? It is hypothesized that six weeks after admission, CBASPersonalized will evoke significant reduction in depressive symptomatology (according to the 24-item version of the Hamilton Rating Scale of Depression, HRSD). The feasibility (acceptance and subjective experience) is assessed on the basis of the dropout rate and a self-assessed questionnaire, which measures satisfaction with and subjective effectiveness of the specific treatment components.
In addition, moderator, process and long-term analyses will be conducted for differential insights. Primary and secondary outcome will be analyzed using analysis of covariance (ANCOVA) controlling for pre-treatment scores. Moderator and process analyses will be performed using multiple regression and linear mixed models.
As a specific secondary research question, we will examine the associations between childhood maltreatment (CM), depression severity, and potential psychological mechanisms of this associations (emotion regulation, self-compassion, empathic distress, interpersonal problems) at the beginning of treatment. In addition, we will explore which changes in the potential psychological mechanisms are particularly closely related to changes in depressive symptoms.
As another additional research question, we will examine the associations between the state-like therapeutic alliance, trait-like alliance, and depression severity. We want to explore these associations as a possible effect mechanism and specify a possible transfer to CBASP specific mechanisms of actions.
Finally, the analyses of the outcomes at the end of the six-to-twelve week blended online-aftercare and the follow-up survey 6 months after end of treatment will provide important results on the blended after-care program as well as longterm treatment outcome. Of note, we will evaluate the online continuation treatment CBASPersonalized@home regarding feasibility. Therefore, patients' expectations towards the intervention, their adherence (completed modules and exercises), acceptance and satisfaction with the intervention as well as the perceived fit and perceived effectiveness and usability of the intervention will be analyzed. Depression severity at the beginning of CBASPersonalized@home, expectations, satisfaction and therapeutic alliance will be analyzed as possible predictors of adherence. A possible relationship between changes in depressive symptoms in the course of the continuation treatment and adherence will be explored.
- Conditions
- Persistent Depressive Disorder
- Being tested
- CBASPersonalized
- Keywords
- persistent depressive disorder, psychotherapy, cognitive behavioral therapy, inpatient treatment, childhood maltreatment, treatment-resistance, clinical effectiveness, personalized psychotherapy, comorbidity, cognitive behavioral analysis system of psychotherapy, online aftercare
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBASPersonalizedOther
Also called Drug
In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.
After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.
Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented.
| Study group | Role | What they receive |
|---|---|---|
| CBASPersonalized | Other | Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient. Receives: Other: CBASPersonalized |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hamilton Rating Scale of Depression, 24-item version (HRSD-24)
The change in HDRS-24 item score (Hamilton, 1960; Williams, 1988) from baseline to 6 weeks after study start will be the primary endpoint. The HRSD-24 is a semi-structured interview which is used to measure the severity of all symptom domains of depression as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) over a period of the last 7 days. It shows good psychometric properties. The HRSD-24 will be conducted by blind study raters at every time point. Raters evaluate symptom severity on a scale from 0 to 2 or 0 - 3 or 0 - 4 for each item, with higher number indicating higher symptom severity. The total score ranges from 0 to 75 with higher values indicating higher depression severity.
Measured: The primary outcome is given by the post value (week six: end of inpatient treatment) in the HRSD24.
Secondary outcomes (21)
Beck Depression Inventory-II (BDI-II)
Self-report instrument to assess the severity of depression on 21 items, each symptom represents one item with responses from 0 (symptom absent) to 4 (symptom present). The total score ranges from 0 to 63 with higher values indicating more severe depressive symptoms.
Measured: Baseline, 2, 4, 6, 8, 9, 14, and 37 weeks after study start
Montgomery Asberg Depression Rating Scale (MADRS)
Observer-report instrument to assess the severity of depression (symptom areas: apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts) on a 7-point Likert scale with 6 representing highest severity. In the applied MADRS+ version, three items assessing helplessness, hopelessness and worthlessness are added. Hence, the total score of MADRS+ ranges from 0 - 71 with higher values indicating more severe depression.
Measured: Baseline, 2, 4, 6, 14, and 37 weeks after study start
Brief Symptom Inventory (BSI)
Self-report questionnaire to assess general psychopathological symptom severity in nine different symptom dimensions (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism, general severity score) on a scale from 0 to 4 with 4 representing more severe symptoms. A global indicator is the General Severity Index (GSI) which will be used as a total score here. The GSI is given by the mean of all subscales and ranges from 0 (low general symptom severity) to 4 (high severity).
Measured: Baseline, 6, 14, and 37 weeks after study start
Patient Health Questionnaire (PHQ)
Self-report questionnaire for the assessment of various mental health conditions (factors are somatic, anxiety and depression symptom scales), responses are given on a scale from 0 to 2 (with 2 representing higher symptom severity)
Measured: Baseline, 6, 14, and 37 weeks after study start
Inventory of Personality Organization (IPO-16)
Self-report measure for the assessment of personality dysfunction in three domains (identity, defense, reality-testing)
Measured: Baseline, 6, 14, and 37 weeks after study start
revised Impact of Event Scale (IES-R)
self-report of post-traumatic stress symptoms with the three subdomains intrusions, avoidance and over-arousal; a scoring scheme with intervals of 0 (not at all), 1 (rarely), 3 (sometimes), and 5 (often) is used to reflect frequency of symptoms over the past week. Subscales are analyzed by summing up all responses of items that belong to one subscale. Intrusion and hyperarousal range between 0 - 35 and avoidance ranges between 0 - 40, with higher values indicating more severe intrusion/ hyperarousal/ avoidance.
Measured: Baseline, 6, 14, and 37 weeks after study start
Social Support Questionnaire F-SozU
self-report to assess perceived social support on the four scales emotional and practical support, social integration, and social stress. Additional scales are reciprocity, availability of a trusted person, satisfaction with social support. Contains 54 items; responses are given on a 5-point Likert scale. Patients indicate their level of agreement with a presented statement from 0 (totally disagreed) to 4 (totally agreed). The total range is from 0 to 216 with higher values representing higher perceived and received social support.
Measured: Baseline, 6, 14, and 37 weeks after study start
Depressive Expectations Scale (DES)
self-report to assess intensity of dysfunctional expectations (regarding social rejection/ support, mood regulation and the ability to perform). The DES consists of 25 items. Responses are given on a 5-point Likert-scale where patients express their agreement with a given statement (1= I don't agree to 5= I agree). The total score varies between 0 and 125 with higher values indicating higher intensity of dysfunctional expectations.
Measured: Baseline, 6, 14, and 37 weeks after study start
Difficulties in Emotion Regulation Scale (DERS)
self-report to assess the flexibility and adaptiveness of emotion regulation. The DERS consists of 36 items. Responses are given on a 5-point Likert-scale where patients indicate how often the following statements apply to them (1= almost never (0-10%) to 5= almost always (91-100%). The total score varies between 0 and 180 with higher scores suggesting greater problems with emotion regulation.
Measured: Baseline, 6, 14, and 37 weeks after study start
revised Adult Attachment Scale (AAS-R)
self-report to assess individual's attachment style on the subscales closeness, trust and anxiety; on a scale from 1 (not at all true) to 5 (very true). There are 15 items in total with 5 belonging to each subscale. Higher values reflect higher comfort with closeness or depending on others or concern about abandonment.
Measured: Baseline, 6, 14, and 37 weeks after study start
Self-Compassion Scale-Short Form (SCS-SF)
self-report to assess six components of self-compassion (self-kindness, self-judgement, common humanity, isolation, mindfulness, over-identification). Response format ist a 5-point Likert-type scale ranging from 1 (almost never) to 5 (almost always). Total scores can range between 0 and 60 with higher values representing higher levels of self-compassion.
Measured: Baseline, 6, 14, and 37 weeks after study start
Impact Message Inventory (IMI-R)
observer-rated questionnaire designed to measure distinctive internal reactions, referred to as impact messages, that interactants experience to the full range of interpersonal behaviours indexed along the circumplex of the interpersonal circle with the 2 dimensions dominance-submissiveness and friendliness-hostility. Messages are rated on a scale from 0 (not at all) to 4 (very much). The total score of each subscale is considered for analysis.
Measured: Baseline, 6, 14, and 37 weeks after study start
Measure of Disorders of Capacity as defined by the International Classification of Functioning (MINI-ICF)
observer-rated questionnaire to measure quality of life and functioning, framed as skill deficits in 12 areas (e.g. skill to adapt to rules and routines, professional and non-professional skills, assertiveness, endurance etc.) Skill deficits are assessed using a response scale from 0 (no skill deficits) to 4 (complete absence of skill)
Measured: Baseline, 6, 14, and 37 weeks after study start
Health-related quality of life (EQ-5D-5L)
self-rated questionnaire to measure health-related quality of life. Health is assessed using 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression. For each dimensions, participants can select one option out of 5 that describes them best.
Measured: Baseline, 6, 14, and 37 weeks after study start
Euthymia Scale (ES)
self-rated questionnaire to assess euthymia. It contains 10 items which assess factors of general mood, energy and coping with stressors. Responses are given by selecting (True/ False) for a specific statement. The total range of the ES is from 0 to 10 with 10 indicating higher prevalence of euthymia.
Measured: Baseline, 6, 14, and 37 weeks after study start
Working Alliance Inventory (WAI-SR)
Self-rated questionnaire administered to patients (WAI-C) and therapists (WAI-T) to assess the quality of the working alliance based on Bordin's pan theoretical concept via 3 subscales (12 items each): a)goals: agreement about the goals of therapy; b)tasks: agreement about the tasks of therapy, c)bond: bond between therapist and patient. Responses are given on a 7-point Likert scale (1= totally disagree, 7= totally agree). Mean scores are analysed for all 3 subscales and on an overall level, with higher values indicating higher satisfaction with the therapeutic alliance.
Patient expectations of alliance are assessed via an adapted form of the WAI-SR (WAI-expected; WAI-e) prior to the start of therapy at an initial assessment (T0). The instructions are altered by adding the following sentence: "Since you have not yet received any therapy through this study, we ask you to think about what you expect from the therapy in answering the following questions."
Measured: T0 for WAI-e; WAI-C and WAI-T at 1, 2, 3, 4, 5, 6; WAI-C at 13, and 37 weeks after study start
Global Assessment of Functioning (GAF)
observer-rated questionnaire to measure functioning in 9 descriptors (work, law, social (family and friends), judgement, thinking, mood, anxiety, hallucinations, suicidal ideation). Each descriptor has a 9-point range from 0 (most severe) to 90 (least severe)
Measured: Baseline, 6, 14, and 37 weeks after study start
PATHEV (Patient Therapy Expectation and Evaluation questionnaire)
The PATHEV is a questionnaire measuring patient expectations on three scales: (1) hope of improvement, (2) fear of change, and (3) suitability (Schulte, 2005). It consists of 11 items and is rated on a 5-point Likert scale. The instrument has shown acceptable to good reliability (Cronbachs Alpha 0.73- 0.89). Construct validity of the scales has been demonstrated via three studies.
Measured: The PATHEV is administered at an initial assessment (T0), prior to the start of therapy.
WAI-e (WAI-expected)
Patient expectations of alliance were assessed by an adapted form of the WAI-SR (WAI-expected, WAI-e).
The instructions were altered by adding the following sentence: "Since you have not yet received any therapy through this study, we ask you to think about what you expect from the therapy in answering the following questions."
Measured: Assessed prior to the start of therapy at an initial assessment (T0).
Interpersonal Reactivity Index (IRI)
To assess dispositional empathic traits, a shortened and validated German version of the interpersonal reactivity index (IRI) self-report survey is used (Davis, 1980; German Version: Paulus, 2009). The questionnaire measures the four domains (1.) perspective-taking, (2.) empathic concern, (3.) personal distress, and (4.) fantasy with four items per subscale.
Measured: Baseline, 6, 14, and 37 weeks after study start
Evaluation of CBASPersonalized inpatient treatment
A self-constructed questionnaire concerning patients' fit, acceptance and satisfaction is used to evaluate the CBASPersonalized inpatient treatment. Patients are asked to evaluate the therapy components individually according to these three criteria. All items were answered on a 6-level Likert scale.
Measured: At the end of the inpatient treatment, 6 weeks after study start
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2018
- Study start1 Apr 2019
- Primary completion31 Dec 2020 (estimated)
- Study completion30 Sep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Persistent Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- In the proposed prospective, mono-site, evaluator-blinded study, 100 PDD patients will be included. The study addresses the primary research question: Is the six-week inpatient CBASPersonalized-treatment effective in PDD? It is hypothesized that six weeks after randomization, CBASPersonalized will evoke significant reduction in depressive symptomatology. In addition, feasibility will be examined and differential indication by moderator, process and long-term analyses will be investigated. A follow-up survey six months after end of treatment will provide important results on long-term treatment outcome.
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Philipps University Marburg
- Sponsor type
- University, hospital or other
- Collaborators
- Schön Klinik Bad Arolsen
- Responsible party
- Sponsor
- Investigators
- Eva-Lotta Brakemeier, Prof. Dr., Study chair, University Greifswald and Philipps University MarburgJörg-Tobias Hof, Principal investigator, Schön Klinik Bad Arolsen (study site)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03616665
- Sponsor's protocol ID
- 2018_14k
- Acronym
- PePsy
- Status last verified
- Sep 2020
- First submitted
- 28 Jun 2018
- Last updated
- 14 Sep 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual patient data will be shared with researchers providing a clinical relevant and methodological sound proposal.
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Effectiveness of a Personalized Inpatient Program Tailored for Persistent Depressive Disorder With Childhood Maltreatment and Comorbidity: Personalized Cognitive Behavioral Analysis System of Psychotherapy
- ClinicalTrials.gov ID
- NCT03616665
- Acronym / sponsor ID
- PePsy / 2018_14k
- Conditions
- Persistent Depressive Disorder
- Keywords
- persistent depressive disorder, psychotherapy, cognitive behavioral therapy, inpatient treatment, childhood maltreatment, treatment-resistance, clinical effectiveness, personalized psychotherapy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Philipps University MarburgUniversity, hospital or other
- Collaborators
- Schön Klinik Bad Arolsen
- Study start
- 1 Apr 2019 (actual)
- Primary completion
- 31 Dec 2020 (estimated)
- Study completion
- 30 Sep 2021 (estimated)
- First posted
- 6 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The major objective of this study is to evaluate a new conceptualized personalized concept of Cognitive Behavioral Analysis System of Psychotherapy (CBASPersonalized) in the treatment of patients with persistent depressive disorder (PDD), childhood maltreatment and a high rate of comorbidity. Patients receive a two-phase-treatment-program (six-weeks inpatient-treatment and six-to-twelve-weeks blended-online-aftercare) in combination with standardized pharmacotherapy in a routine clinical inpatient setting. This study addresses the primary research question: Is an intensive six-week inpatient CBASPersonalized treatment feasible and effective in a clinical sample of PDD patients? In addition, moderator, process and long-term analyses will be conducted for differential insights.
Detailed description
Background: Persistent depressive disorder (PDD) is a prevalent disabling disorder. Given its high degree of treatment-resistance (TR), comorbidity, and suicidality, this patient group constitutes a massive health problem. The Cognitive Behavioral Analysis System of Psychotherapy (CBASP) was specifically developed for the outpatient treatment of PDD showing superiority to active control groups in some studies. However, non-remission and relapse rates of CBASP are relatively high, which might be caused by the fact that within the original CBASP-concept the frequent comorbid disorders are not sufficiently addressed. Thus, an optimized personalized short and intensive CBASP-concept (CBASPersonalized) was established including the interpersonal CBASP-strategies while adding evidence-based intrapersonal strategies being tailored to the specific comorbid problems. In this study, the investigators will evaluate the feasibility and effectiveness of CBASPersonalized. Patients will receive a six-week inpatient treatment followed by a six-to-twelve-week blended-online-aftercare (CBASPersonalized@home) in combination with standardized pharmacotherapy in a routine clinical inpatient setting.
Methods: In the proposed prospective, mono-site study, 100 PDD patients with childhood maltreatment will be included. The study addresses the primary research question: Is an intensive six-week inpatient CBASPersonalized treatment feasible and effective in a clinical sample of PDD patients? It is hypothesized that six weeks after admission, CBASPersonalized will evoke significant reduction in depressive symptomatology (according to the 24-item version of the Hamilton Rating Scale of Depression, HRSD). The feasibility (acceptance and subjective experience) is assessed on the basis of the dropout rate and a self-assessed questionnaire, which measures satisfaction with and subjective effectiveness of the specific treatment components.
In addition, moderator, process and long-term analyses will be conducted for differential insights. Primary and secondary outcome will be analyzed using analysis of covariance (ANCOVA) controlling for pre-treatment scores. Moderator and process analyses will be performed using multiple regression and linear mixed models.
As a specific secondary research question, we will examine the associations between childhood maltreatment (CM), depression severity, and potential psychological mechanisms of this associations (emotion regulation, self-compassion, empathic distress, interpersonal problems) at the beginning of treatment. In addition, we will explore which changes in the potential psychological mechanisms are particularly closely related to changes in depressive symptoms.
As another additional research question, we will examine the associations between the state-like therapeutic alliance, trait-like alliance, and depression severity. We want to explore these associations as a possible effect mechanism and specify a possible transfer to CBASP specific mechanisms of actions.
Finally, the analyses of the outcomes at the end of the six-to-twelve week blended online-aftercare and the follow-up survey 6 months after end of treatment will provide important results on the blended after-care program as well as longterm treatment outcome. Of note, we will evaluate the online continuation treatment CBASPersonalized@home regarding feasibility. Therefore, patients' expectations towards the intervention, their adherence (completed modules and exercises), acceptance and satisfaction with the intervention as well as the perceived fit and perceived effectiveness and usability of the intervention will be analyzed. Depression severity at the beginning of CBASPersonalized@home, expectations, satisfaction and therapeutic alliance will be analyzed as possible predictors of adherence. A possible relationship between changes in depressive symptoms in the course of the continuation treatment and adherence will be explored.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- In the proposed prospective, mono-site, evaluator-blinded study, 100 PDD patients will be included. The study addresses the primary research question: Is the six-week inpatient CBASPersonalized-treatment effective in PDD? It is hypothesized that six weeks after randomization, CBASPersonalized will evoke significant reduction in depressive symptomatology. In addition, feasibility will be examined and differential indication by moderator, process and long-term analyses will be investigated. A follow-up survey six months after end of treatment will provide important results on long-term treatment outcome.
| Arm | Type | Receives |
|---|---|---|
| CBASPersonalized | Other | Other: CBASPersonalizedWithin the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Primary diagnosis of persistent depressive disorder (PDD) according to DSM-5
- Experiences of childhood maltreatment (>Cut-off criteria in one of 5 scales of the Childhood Trauma Screener (CTS))
- Sufficient German language skills
- Have read and signed an informed consent form
Key exclusion criteria (3 listed)
- Life-time diagnosis of an schizophrenia or schizophrenic spectrum disorder according to DSM-5
- Life-time diagnosis of a schizoid, schizotypal or antisocial personality disorder according to DSM-5
- Consumption of legal (e.g. alcohol) or illegal substances during the inpatient stay
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBASPersonalizedAlso: DrugIn addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses. After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home. Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented. | Other | CBASPersonalized |
Primary outcome
Hamilton Rating Scale of Depression, 24-item version (HRSD-24)
Time frame: The primary outcome is given by the post value (week six: end of inpatient treatment) in the HRSD24.
The change in HDRS-24 item score (Hamilton, 1960; Williams, 1988) from baseline to 6 weeks after study start will be the primary endpoint. The HRSD-24 is a semi-structured interview which is used to measure the severity of all symptom domains of depression as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) over a period of the last 7 days. It shows good psychometric properties. The HRSD-24 will be conducted by blind study raters at every time point. Raters evaluate symptom severity on a scale from 0 to 2 or 0 - 3 or 0 - 4 for each item, with higher number indicating higher symptom severity. The total score ranges from 0 to 75 with higher values indicating higher depression severity.
21 secondary outcomes
Beck Depression Inventory-II (BDI-II)
Time frame: Baseline, 2, 4, 6, 8, 9, 14, and 37 weeks after study start
Montgomery Asberg Depression Rating Scale (MADRS)
Time frame: Baseline, 2, 4, 6, 14, and 37 weeks after study start
Brief Symptom Inventory (BSI)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Patient Health Questionnaire (PHQ)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Inventory of Personality Organization (IPO-16)
Time frame: Baseline, 6, 14, and 37 weeks after study start
revised Impact of Event Scale (IES-R)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Social Support Questionnaire F-SozU
Time frame: Baseline, 6, 14, and 37 weeks after study start
Depressive Expectations Scale (DES)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Difficulties in Emotion Regulation Scale (DERS)
Time frame: Baseline, 6, 14, and 37 weeks after study start
revised Adult Attachment Scale (AAS-R)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Self-Compassion Scale-Short Form (SCS-SF)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Impact Message Inventory (IMI-R)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Measure of Disorders of Capacity as defined by the International Classification of Functioning (MINI-ICF)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Health-related quality of life (EQ-5D-5L)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Euthymia Scale (ES)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Working Alliance Inventory (WAI-SR)
Time frame: T0 for WAI-e; WAI-C and WAI-T at 1, 2, 3, 4, 5, 6; WAI-C at 13, and 37 weeks after study start
Global Assessment of Functioning (GAF)
Time frame: Baseline, 6, 14, and 37 weeks after study start
PATHEV (Patient Therapy Expectation and Evaluation questionnaire)
Time frame: The PATHEV is administered at an initial assessment (T0), prior to the start of therapy.
WAI-e (WAI-expected)
Time frame: Assessed prior to the start of therapy at an initial assessment (T0).
Interpersonal Reactivity Index (IRI)
Time frame: Baseline, 6, 14, and 37 weeks after study start
Evaluation of CBASPersonalized inpatient treatment
Time frame: At the end of the inpatient treatment, 6 weeks after study start
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2020.
- Individual participant dataSharing planned: Yes. Individual patient data will be shared with researchers providing a clinical relevant and methodological sound proposal.
Related trials for Persistent Depressive Disorder
Not yet recruiting
Virtual Pain Education for Spinal Cord Stimulation Patients
Chronic Pain, Chronic Pain Due to Injury
Active, not recruitingObservational study
Health Surveillance at Constructor University Bremen (CUB)
Social Isolation or Loneliness, Anxiety
Not yet recruitingEarly Phase 1
Individualized fMRI-guided TMS for Depression
Depression, Major Depressive Disorder (MDD)
Not yet recruiting
CODEPAD-III (Collaborative Outcomes of DEpression and Pain Associated With Delivery-III)
Depression, Postpartum
Active, not recruitingObservational study
Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery
Breast Cancer, Chronic Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eva-Lotta Brakemeier, Prof. Dr. study chair
University Greifswald and Philipps University Marburg
Jörg-Tobias Hof principal investigator
Schön Klinik Bad Arolsen (study site)
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CBASPersonalized in people with Persistent Depressive Disorder, run by Philipps University Marburg at 2 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Eva-Lotta Brakemeier, Prof. Dr. (+491711278600, eva-lotta.brakemeier@uni-greifswald.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hamilton Rating Scale of Depression, 24-item version (HRSD-24) (time frame: The primary outcome is given by the post value (week six: end of inpatient treatment) in the HRSD24.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2020.